Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651283 | 0.90 | MAPK8 (0.40) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL5647564 | 0.87 | MAPK8 (0.47) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL5651276 | 0.86 | PLAT (0.40) | MAPTHPGDSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL5651246 | 0.84 | SMN1; SMN2 (0.42) | HPGDSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL5651454 | 0.77 | ALDH1A1 (0.54) | LMNAMAPTSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL2781580 | 0.76 | CNR2 (0.43) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL5652931 | 0.76 | ACACB (0.53) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL5648783 | 0.76 | LMNA (0.45) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL5653687 | 0.76 | ALDH1A1 (0.51) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL1266627 | 0.75 | MAPT (0.44) | MAPTHPGDSMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | disclosed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | MAPK1, ALK, NAT1 | LMNA 1417/4885MAPT 3795/4885HPGD 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.